Prothena Corp. (PRTA) Trading Down 7.1%
Prothena Corp. (NASDAQ:PRTA)’s share price was down 7.1% on Wednesday . The company traded as low as $43.83 and last traded at $44.25, with a volume of 271,621 shares traded. The stock had previously closed at $47.65.
A number of equities analysts recently weighed in on PRTA shares. Credit Suisse Group AG restated a “buy” rating on shares of Prothena Corp. in a report on Tuesday. Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corp. in a report on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Prothena Corp. from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. Wedbush restated an “outperform” rating and set a $77.00 target price on shares of Prothena Corp. in a report on Tuesday, July 5th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $77.00 target price on shares of Prothena Corp. in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $74.60.
The company’s market capitalization is $1.49 billion. The company has a 50-day moving average price of $43.40 and a 200-day moving average price of $42.27.
Prothena Corp. (NASDAQ:PRTA) last issued its earnings results on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.04. Equities analysts predict that Prothena Corp. will post ($3.72) EPS for the current year.
In related news, Director Dennis J. Selkoe sold 5,000 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the transaction, the director now directly owns 3,025 shares in the company, valued at approximately $136,125. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Several institutional investors have recently modified their holdings of PRTA. Jennison Associates LLC boosted its position in shares of Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock worth $27,699,000 after buying an additional 1,912 shares in the last quarter. Pinnacle Associates Ltd. purchased a new position in shares of Prothena Corp. during the fourth quarter worth about $20,194,000. Wells Fargo & Company MN boosted its position in shares of Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock worth $16,730,000 after buying an additional 234,667 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Prothena Corp. by 36.9% in the fourth quarter. Columbus Circle Investors now owns 218,943 shares of the company’s stock worth $14,912,000 after buying an additional 58,987 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Prothena Corp. by 214.0% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock worth $6,246,000 after buying an additional 62,500 shares in the last quarter.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.